 |
| China Antibiotic Market Report, 2008-2009 |
|
|
|
|
|||||||||||||
|
|
|||||||||||||
|
From the perspective of industrial scale, China's output and production capacity of antibiotic raw materials ranks the NO.1 in the world. In 2007, China's sales revenue of antibiotic raw materials reached CNY35 billion, of which CNY14.8 billion were from exports, accounting for 25% of the total export value of all pharmaceutical raw materials. China's potential production capacity of penicillin is approaching 100,000 tons. Among which, semi-synthetic penicillin and cephalosporins account for more than 50% of the global market share. Total production capacity of 6-APA, terramycin, amoxicillin and cephalosporins intermediates and pharmaceutical raw materials in China is over 10,000 tons. China's potential production capacity of penicillin industrial salt is close to 100,000 tons, and the market concentration reaches 80 percent.
According to the statistics of the National Bureau of Statistics, revenue and profit of China's pharmaceutical industry both increased in the first eleven months of 2007. Especially sales profit rose 51% year on year, while that grew only 11% in 2006. In 2007, China pharmaceutical industry was booming, and the year of 2008 continues the momentum. In the first three quarters of 2007, the results of a sample survey by large medical institutions show that most of the traditional, large bulk and low-priced antibiotics, such as cephalexin, cefradine, cefazolin and amoxicillin, have failed to enter the top 20. However, those antibiotics like Cefotiam, Cefminox, Cefepime and Meropenem, normally regarded as small variety of antibiotics, were all on the top 20. By the year of 2010, the sales of quinolones are expected to exceed cephalosporins, which is the best selling of antibiotics in the current market. Quinolones anti-infective drugs have grown rapidly in recent years, accounting for 18.5% of global anti-infective drug market. 1. China Antibiotics Market In Globalization Process, 2009
1.1 Impact of Globalization on China Pharmaceutical Market 1.1.1 Pharmaceutical Industry Restructuring and International Division of Labor 1.1.2 International Status of China Pharmaceutical Industry 1.1.3 Forecast of China Status in Global Pharmaceutical Industry, 2009 1.2 China Pharmacy Quality Management and Globalization, 2009 1.3 China Bulk Drug Trade and Globalization, 2008 2. China Antibiotics Foreign Trade, 2007-2008 2.1 General Trend of China Antibiotic Import & Export 2.1.1 Import Value 2.1.2 Export Value 2.1.3 Import Volume 2.1.4 Export Volume 2.2 China Foreign Trade Structure 2.2.1 General Trade Trend 2.2.2 General Trade Trend in All Global Regions 2.3 China Export Region Structure 2.4 Trade Mode Structure 3. China Antibiotics Market, 2008 4. China Antibiotics Market after 2010 5. China Anti-Infective Drug Market 6. China Antibiotics Retail Market 6.1 Overall Situation 6.2 Sales Situation 7. Children Oral Antibiotics Market 7.1 Categories and Varieties 7.2 Ladder Development of Children Antibiotics 7.3 Famous Brands 7.4 Suggestion on Development 8. Cephalosporins Antibiotics Market 8.1 Cephalosporins Antibiotics Market 8.1.1 Overview 8.1.2 Main Types 8.1.3 Price Analysis 8.1.4 Development Trend 8.2 Market of Main Products 8.2.1 Main Categories 9. Penicillin Antibiotics Market 9.1 Advertisement Placement 9.2 Competition 9.3 Semi-Synthetic Penicillin Market 10. Carbapenem Antibiotics Market 11.1 Market Development 11.2 Main Products 11.3 Market Size 11. Macrolide Antibiotics Market 11.1 Azithromycin 11.2 Roxythromycin 12. Quinolones Antibiotics Market 12.1 Main Types 12.2 Application 12.3 Production Statistics 12.3.1 Raw Materials 12.3.2 Preparations 12.4 Applications in Sample Hospitals 12.4.1 Overview 12.4.2 Types 12.5 Development Trend 13. β-lactams Antibiotics Market 13.1 Total Used-drug Volume and Growth in Three Years 13.2 Total Value and Proportions in Three Years 13.3 Types in the Top of Ranking list in Terms of Meditation Value 13.4 DDDs in the Top of Ranking list 13.5 Top 10 Companies in Terms of Sales Value 14. Polypeptide Antibiotics Market 14.1 Glycopeptide Antibiotics 14.2 Vancomycin 14.2.1 Vancomycin 14.2.2 Norvancomycin 14.2.3 Teicoplanin 15. Market Competition 15.1 Market Competition of Cephalosporins Bulk Drugs 15.2 Main Companies 15.2.1 Yangtze River Pharmaceutical Group 15.2.2 Shanghai Roche Pharmaceuticals Co. 15.2.3 Shenzhen Pharmaceutical Works 15.2.4 Anhui Welman Pharmaceuticals Co. 15.2.5 Zhuhai Livzon Pharmaceuticals Co. 15.2.6 Beijing Double-Crane Pharmaceuticals Co. 15.2.7 Harbin Pharmaceutical Group |
|||||||||||||
| < Prev | Next > |
|---|
